Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trial.
about
A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar® Gel) in nephrotic syndrome due to idiopathic membranous nephropathy.Repository corticotropin injection in a patient presenting with focal segmental glomerulosclerosis, rheumatoid arthritis, and optic neuritis: a case report.Focal segmental glomerulosclerosis: molecular genetics and targeted therapiesSynthetic ACTH in High Risk Patients with Idiopathic Membranous Nephropathy: A Prospective, Open Label Cohort Study.Acthar gel in the treatment of nephrotic syndrome: a multicenter retrospective case series.Pharmacological treatment of primary membranous nephropathy in 2016.Update on immunoglobulin a nephropathy. Part II: Clinical, diagnostic and therapeutical aspects.Adrenocorticotropic hormone gel in the treatment of systemic lupus erythematosus: A retrospective study of patients.MC1R is dispensable for the proteinuria reducing and glomerular protective effect of melanocortin therapy.Adrenocorticotropic hormone analog use for podocytopathiesH.P. Acthar Gel (repository corticotropin injection) treatment of patients with multiple sclerosis and diabetesPneumococcal hemolytic uremic syndrome and steroid resistant nephrotic syndrome.Treatment of idiopathic FSGS with adrenocorticotropic hormone gel.Leveraging melanocortin pathways to treat glomerular diseases.Adrenocorticotropic hormone therapy for the treatment of idiopathic nephrotic syndrome in children and young adults: a systematic review of early clinical studies with contemporary relevance.New diagnostic tests and new therapies for glomerular diseases.Glomerular diseases: membranous nephropathy--a modern viewOverview of current and alternative therapies for idiopathic membranous nephropathy.Acquired Resistance to Corticotropin Therapy in Nephrotic Syndrome: Role of De Novo Neutralizing Antibody.Clinical and Economic Evaluation of Repository Corticotropin Injection: A Narrative Literature Review of Treatment Efficacy and Healthcare Resource Utilization for Seven Key IndicationsThe Role of Alpha-MSH as a Modulator of Ocular Immunobiology Exemplifies Mechanistic Differences between Melanocortins and Steroids.Efficacy and safety of adrenocorticotropic hormone treatment in glomerular diseases: a systematic review and meta-analysis.Why, when and how should immunosuppressive therapy considered in patients with immunoglobulin A nephropathy?Low-dose synthetic adrenocorticotropic hormone-analog therapy for nephrotic patients: results from a single-center pilot study.ACTH action on podocytes: mystery solved?A case report of adrenocorticotropic hormone to treat recurrent focal segmental glomerular sclerosis post-transplantation and biomarker monitoring.Melanocortin 1 receptor agonist protects podocytes through catalase and RhoA activation.Treatment of primary membranous nephropathy: where are we now?Subcutaneous repository corticotropin gel for non-infectious panuveitis: Reappraisal of an old pharmacologic agent.
P2860
Q33932604-32D0AAF1-1032-4804-88BB-8ACD49401506Q35219562-553AE297-37B7-447E-96D3-136A5D627688Q35686453-AA902575-D8DD-4BE6-8590-69E766FE930AQ35840057-9B944728-B67F-481D-B027-C62F9B1C4922Q35976834-7BA120EC-279A-4B31-8D24-71FA61A2C5D4Q36106413-6E420A48-5584-4170-97BA-7304F24FF47CQ36447934-10E7615B-B95F-4E7B-8043-0E7BD0286D4EQ36851414-9C58A1F2-0446-4DF7-88D8-79A92CBCB811Q36980645-31D0C773-1062-4E46-BEAB-45A8A37C849CQ37070458-B5ADC92E-C7FE-4ABD-85CC-304A3B9AD340Q37072620-13F53C3C-FB63-48E1-B92D-CD494508644CQ37119048-C216231B-418C-4B5B-A33D-369B9F34B3D5Q37359035-E646B581-EDE0-4B74-9C04-FBE32AD1894EQ37632054-1A77D4DA-5041-4939-B38D-96047085FA68Q37651364-3D2D6D2E-6507-4B90-9C16-889A6D061FDFQ38076221-E2452C7F-0953-4D78-8AAB-7CAF052EA48FQ38118221-95555372-807B-43B3-874F-9A01F11504EFQ38425865-12274AC2-6094-4751-BABF-B0129DBE5D58Q38667777-4614F8E5-07AB-4CE4-9D77-46738A9A13D1Q38703169-F2A399FA-CE88-4749-B2C0-E4A041C96190Q38710638-FB0ECC2F-D3D5-4660-95A8-5B885850A985Q38858772-2E6FC2A4-3405-4CFB-A310-4170972E9B8EQ38860793-FBEBED12-7AB9-4943-A349-190DA54910E5Q41467613-60224ADE-4136-42D4-B191-C628D880253EQ41839449-31F7BBA3-1D9B-4001-AD32-E8141C38A145Q43195589-312F8D52-8B45-4679-B95D-8C9AB41B72A4Q46594445-8681A023-6917-4EA5-A72B-8DB2442E9F17Q47850601-20F46F95-DB35-4A98-B641-BDB76B76D463Q50334146-C881B97C-1B60-4041-8638-110C7A3BB5C3
P2860
Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trial.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Treatment of resistant glomeru ...... mone gel: a prospective trial.
@en
Treatment of resistant glomeru ...... mone gel: a prospective trial.
@nl
type
label
Treatment of resistant glomeru ...... mone gel: a prospective trial.
@en
Treatment of resistant glomeru ...... mone gel: a prospective trial.
@nl
prefLabel
Treatment of resistant glomeru ...... mone gel: a prospective trial.
@en
Treatment of resistant glomeru ...... mone gel: a prospective trial.
@nl
P2093
P2860
P50
P356
P1476
Treatment of resistant glomeru ...... mone gel: a prospective trial.
@en
P2093
Andrew S Bomback
Gerald B Appel
Jai Radhakrishnan
P2860
P356
10.1159/000339287
P577
2012-06-19T00:00:00Z